Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

<p>Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to develop innovative technologies for analyzing, targeting, probing, handling, or quality control of biospecimens used in cancer research or clinical care. The emphasis of this NOFO is on early-stage projects proposing proof-of-concept/pilot studies to test the feasibility of the proposed method, tool, assay, platform, or instrument. Well-suited applications must offer a high degree of technical innovation and the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may have potential for widespread applicability but must be focused in this proposal on cancer applications. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.&nbsp;</p>